Articole cu mandate pentru acces public - Professor William M. GallagherAflați mai multe
Nu sunt disponibile nicăieri: 33
Examinați
p53 as a target for the treatment of cancer
MJ Duffy, NC Synnott, PM McGowan, J Crown, D O’Connor, ...
Cancer treatment reviews 40 (10), 1153-1160, 2014
Mandate: Science Foundation Ireland
Examinați
Automated image analysis in histopathology: a valuable tool in medical diagnostics
L Mulrane, E Rexhepaj, S Penney, JJ Callanan, WM Gallagher
Expert review of molecular diagnostics 8 (6), 707-725, 2008
Mandate: Higher Education Authority, Ireland
Examinați
Epigenetics of malignant melanoma
B Moran, R Silva, AS Perry, WM Gallagher
Seminars in cancer biology 51, 80-88, 2018
Mandate: Science Foundation Ireland, European Commission
Examinați
The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer
DJ Brennan, S Ek, E Doyle, T Drew, M Foley, G Flannelly, DP O’Connor, ...
European journal of cancer 45 (8), 1510-1517, 2009
Mandate: Higher Education Authority, Ireland
Examinați
Therapeutic rationale to target highly expressed CDK7 conferring poor outcomes in triple-negative breast cancer
B Li, T Ni Chonghaile, Y Fan, SF Madden, R Klinger, AE O'Connor, ...
Cancer research 77 (14), 3834-3845, 2017
Mandate: Science Foundation Ireland, Cancer Research UK, UK Medical Research Council …
Examinați
The EMT transcription factor ZEB2 promotes proliferation of primary and metastatic melanoma while suppressing an invasive, mesenchymal-like phenotype
N Vandamme, G Denecker, K Bruneel, G Blancke, Ö Akay, J Taminau, ...
Cancer research 80 (14), 2983-2995, 2020
Mandate: Research Foundation (Flanders)
Examinați
Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007
NC Synnott, MR Bauer, S Madden, A Murray, R Klinger, N O'Donovan, ...
Cancer letters 414, 99-106, 2018
Mandate: Science Foundation Ireland, UK Medical Research Council
Examinați
Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells
N O’Donovan, AT Byrne, AE O’Connor, S McGee, WM Gallagher, J Crown
Investigational new drugs 29, 752-759, 2011
Mandate: Science Foundation Ireland
Examinați
Examining the role of Rac1 in tumor angiogenesis and growth: a clinically relevant RNAi-mediated approach
P Vader, R Van Der Meel, MH Symons, M Fens, E Pieters, KJ Wilschut, ...
Angiogenesis 14, 457-466, 2011
Mandate: Science Foundation Ireland
Examinați
Truncated HER2: implications for HER2-targeted therapeutics
R Zagozdzon, WM Gallagher, J Crown
Drug discovery today 16 (17-18), 810-816, 2011
Mandate: Science Foundation Ireland
Examinați
microRNAs: a new class of breast cancer biomarkers
L Mulrane, R Klinger, SF McGee, WM Gallagher, DP O’Connor
Expert review of molecular diagnostics 14 (3), 347-363, 2014
Mandate: Science Foundation Ireland, Irish Research Council
Examinați
Standardization of models and methods used to assess nanoparticles in cardiovascular applications
KT Fitzgerald, CA Holladay, C McCarthy, KA Power, A Pandit, ...
Small 7 (6), 705-717, 2011
Mandate: Higher Education Authority, Ireland, Science Foundation Ireland
Examinați
Identification of transcription factors associated with castration‐resistance: Is the serum responsive factor a potential therapeutic target?
M Prencipe, SF Madden, A O'Neill, G O'Hurley, A Culhane, D O'Connor, ...
The Prostate 73 (7), 743-753, 2013
Mandate: Science Foundation Ireland
Examinați
The chain length of biologically produced (R)-3-hydroxyalkanoic acid affects biological activity and structure of anti-cancer peptides
E Szwej, M Devocelle, S Kenny, M Guzik, S O’Connor, ...
Journal of biotechnology 204, 7-12, 2015
Mandate: Higher Education Authority, Ireland
Examinați
High sensitivity cytokine detection in acute coronary syndrome reveals up-regulation of interferon gamma and interleukin-10 post myocardial infarction
KD Patel, SP Duggan, CA Currid, WM Gallagher, R McManus, D Kelleher, ...
Clinical Immunology 133 (2), 251-256, 2009
Mandate: Science Foundation Ireland
Examinați
BET inhibition as a rational therapeutic strategy for invasive lobular breast cancer
L Walsh, KE Haley, B Moran, B Mooney, F Tarrant, SF Madden, ...
Clinical Cancer Research 25 (23), 7139-7150, 2019
Mandate: Science Foundation Ireland, Breast Cancer Now, UK, Cancer Research UK …
Examinați
Identification and functional validation of therapeutic targets for malignant melanoma
G Gremel, M Rafferty, TYK Lau, WM Gallagher
Critical reviews in oncology/hematology 72 (3), 194-214, 2009
Mandate: Higher Education Authority, Ireland
Examinați
High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients
K van den Hurk, B Balint, S Toomey, PC O’Leary, L Unwin, K Sheahan, ...
Melanoma Research 25 (3), 189-199, 2015
Mandate: Science Foundation Ireland
Examinați
Emerging role for the Serum Response Factor (SRF) as a potential therapeutic target in cancer
H Azam, L Pierro, M Reina, WM Gallagher, M Prencipe
Expert Opinion on Therapeutic Targets 26 (2), 155-169, 2022
Mandate: Science Foundation Ireland
Examinați
Advances in tissue-based imaging: impact on oncology research and clinical practice
A Rahman, C Jahangir, SM Lynch, N Alattar, C Aura, N Russell, ...
Expert Review of Molecular Diagnostics 20 (10), 1027-1037, 2020
Mandate: Health Research Board, Ireland, Science Foundation Ireland
Informațiile despre publicații și finanțare sunt alese automat de un program informatic